What can the study of arrows tell us about Indigenous culture and history? The Musée du quai Branly collection, which includes 115 arrows from the Southeast and Central U.S. dating back to the 1700s, provides profound insights into the craftsmanship and cultural practices of the time.
These arrows, primarily made from materials such as river cane, hardwood, garfish scales, and deer antler, showcase a lightweight design with thin shafts. This contrasts sharply with later Choctaw arrows, which are known for their thicker and heavier construction. Such differences highlight the evolution of arrow design over time, reflecting changes in hunting practices and available materials.
Interestingly, some arrows in the collection bear teeth marks from the maker, a testament to the hands-on techniques used in their creation 300 years ago. This detail not only adds a human element to the artifacts but also emphasizes the intimate relationship between the maker and their craft.
Most of the arrows were likely intended for small game, as suggested by their construction and materials. This focus on small game hunting indicates the practical needs of Indigenous communities prior to significant historical events such as the Trail of Tears.
The collection is particularly valuable as it dates from before this tragic period in history, offering a rare opportunity to study Indigenous culture in a time of relative stability. The arrows provide a snapshot of the past, allowing researchers to explore the design evolution of Choctaw arrows and their significance in the broader context of Native American history.
In a different context, the term ‘arrow’ also appears in the medical field, particularly in the ARROW study, which examines the efficacy of pralsetinib for treating RET fusion-positive non-small cell lung cancer (NSCLC). The final data from this study indicates robust and durable responses in patients, emphasizing the importance of early biomarker testing.
Dr. Justin F. Gainor noted, “The final data from the ARROW study shows robust and durable responses with a manageable safety profile in patients with RET fusion-positive NSCLC.” This highlights the potential of pralsetinib as a valuable treatment option.
As the study continues to evolve, the implications for treatment strategies in oncology remain significant. Meanwhile, the arrows in the Musée du quai Branly collection continue to tell their own stories, bridging the gap between past and present.
While the future of both the historical artifacts and the medical research is promising, details remain unconfirmed regarding the full impact of these findings on their respective fields.
